Tenderwize
Wróć do wyszukiwania

Open-house discount agreements for Naproxen

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 8 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naproxen, ATC M01AE02

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

For paper submissions, advance fax/scan/email transmission is only deadline-preserving if the original paper documents...

Only pharmaceutical companies are eligible as potential contract partners.

Submission deadline in 8 days

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive open-house discount agreements for pharmaceutical products concerning Naproxen, ATC M01AE02.
  • Supply contract model for a medicinal product discount agreement under § 130a(8) SGB V, as described in the notice.
Pokaż pełne podsumowanie

Open-house supply arrangement for Naproxen (ATC M01AE02) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated suitability requirement. This is explicitly described as a non-exclusive, non-negotiated accession model, not a classic competitive award procedure. No contract value is stated. Submission is possible electronically with a qualified electronic signature or in paper form, with strict monthly cut-off rules and a final deadline of 05.09.2026.

Ryzyka

For paper submissions, advance fax/scan/email transmission is only deadline-preserving if the original paper documents...

Only pharmaceutical companies are eligible as potential contract partners.

Submission deadline in 8 days

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • The signatory's authority must be evidenced by the commercial register extract; otherwise a power of attorney must be provided.

Administrative

  • Submit a signed contract, the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and the signed declaration of reliability.
  • Submissions must be either handwritten on paper or electronically with a qualified electronic signature.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house discount agreements for Naproxen

Single lot covering non-exclusive open-house pharmaceutical discount agreements for the active substance Naproxen (ATC M01AE02). The lot is for supplies and performance is in Germany, Bavaria (DE212). The notice states that all interested pharmaceutical companies meeting the suitability requirement may join on identical terms. Lot information comes from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Oct 2024 - Oct 2026

Kategoria

Pharmaceutical products

Termin

Deadline Sep 05, 2026

Szczegóły zamówienia

Data publikacji
16 Sep 2024
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
558157-2024

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30